The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFrontier Ip Regulatory News (FIPP)

Share Price Information for Frontier Ip (FIPP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 41.50
Bid: 41.00
Ask: 42.00
Change: -2.00 (-4.60%)
Spread: 1.00 (2.439%)
Open: 43.50
High: 43.50
Low: 41.50
Prev. Close: 43.50
FIPP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Grant of options

17 Mar 2023 14:46

RNS Number : 4141T
Frontier IP Group plc
17 March 2023
 

AIM: FIPP

17 March 2023

 

Frontier IP Group plc

("Frontier IP" or the "Group")

 

Grant of options

 

Frontier IP, a specialist in commercialising intellectual property, announces that, on 16 March 2023, the Board granted options over a total of 760,226 ordinary shares of 10 pence each in the Company ("Ordinary Shares") to certain Executive Directors and personnel of the Company (the "Options").

 

The Options have been granted through a combination of:

 

(i) grants under the Frontier IP Group plc Unapproved Share Option Plan 2021, which includes the terms of the Long-Term Incentive Plan ("LTIP") details of which were approved by shareholders at the annual general meeting of the Group held on 9 December 2022; and

 

(ii) grants under the Company's approved Company Share Option Plan (the "CSOP").

 

A total of 643,376 grants have been made, structured as grants of nominal cost options, at a price of 10 pence per share under the terms of the Company's Unapproved Share Option Plan. The exercise period of the options granted commences on 16 March 2026 and expires on 15 March 2033. Further details on the LTIP and the vesting criteria are set out below.

A total of 116,850 Options have been granted under the CSOP (the "CSOP Grants") with an exercise price of 66.5 pence per share, being the closing mid-market price of an existing ordinary share on 15 March 2023, the business day prior to the grant date. The exercise period of the CSOP Grants commences on 16 March 2026 and expires on 15 March 2033.

 

The Options have been granted as follows:

 

Name

 

Position

Number of grants under Unapproved Share Option Plan

Number of grants under CSOP

Total options over Ordinary Shares held following grant

Neil Crabb

Chief Executive Officer

156,485

-

1,228,642

Jackie McKay

Chief Operating Officer

113,504

-

841,936

Jim Fish

Chief Financial Officer

125,188

-

1,049,402

Matthew White

Chief Commercialisation Officer

125,188

-

554,402

Other Company personnel

123,011

116,850

Total Options granted

643,376

116,850

 

The Options have been granted in line with the aim of the Company's remuneration policy which is to incentivise and reward appropriately in order to attract and retain the best people in support of the Group's strategy.

Following the grants detailed above, the Company now has a total of 5,099,064 options outstanding over Ordinary Shares, representing 9.16% of the Company's current issued share capital.

Background and details on LTIP

At the Company's 2022 annual general meeting, the Board received the approval of shareholders for the terms of the LTIP. The LTIP is based on annual awards of performance shares, structured as nominal cost options, with vesting linked 70% to net asset value per share and 30% to total shareholder return measured over 3 financial years.

In order to enable such grants, the terms of the previous unapproved option plan rules were amended to reflect the terms of the LTIP.

The LTIP rules include:

1. a limit of 15% of issued share capital at time of grant on the number of shares that have been issued, or transferred out of treasury, on the exercise of options granted, and in satisfaction of any other awards made under the share schemes operated by the Company during the period of ten years ending on the grant date with no limit to the number of nil or nominal cost awards within the 15% limit; and

 

2. LTIP participants include the executive directors and other Group employees; allocations are made annually from an aggregate award pool, which is limited in size to ensure sufficient shares are available to grant in future years without exceeding the Group's dilution limit of 15% of issued share capital over the prior ten years. The LTIP includes an individual grant limit of 200% of salary in any financial year.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Neil Crabb

2

Reason for the notification

a)

Position/status

Chief Executive Officer

b)

 

Initial notification /Amendment

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Frontier IP Group plc

b)

LEI

213800BRYUKQPJWKJ312

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Identification code

Options over ordinary shares of 10p each in Frontier IP Group Plc

 

Identification code (ISIN) for Frontier IP Group Plc ordinary shares: GB00B63PS212

b)

Nature of the transaction

Grant of options

c)

Price(s) and volume(s)

 Price(s)

Volume(s)

10p

156,485

d)

Aggregated information

- Aggregated volume

- Price

N/A

e)

Date of the transactions

16 March 2023

f)

Place of the transaction

Outside a trading venue

 

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Jackie McKay

2

Reason for the notification

a)

Position/status

Chief Operating Officer

b)

 

Initial notification /Amendment

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Frontier IP Group plc

b)

LEI

213800BRYUKQPJWKJ312

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Identification code

Options over ordinary shares of 10p each in Frontier IP Group Plc

 

Identification code (ISIN) for Frontier IP Group Plc ordinary shares: GB00B63PS212

b)

Nature of the transaction

Grant of options

c)

Price(s) and volume(s)

 Price(s)

Volume(s)

10p

113,504

d)

Aggregated information

- Aggregated volume

- Price

N/A

e)

Date of the transactions

16 March 2023

f)

Place of the transaction

Outside a trading venue

 

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Jim Fish

2

Reason for the notification

a)

Position/status

Chief Financial Officer

b)

 

Initial notification /Amendment

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Frontier IP Group plc

b)

LEI

213800BRYUKQPJWKJ312

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Identification code

Options over ordinary shares of 10p each in Frontier IP Group Plc

 

Identification code (ISIN) for Frontier IP Group Plc ordinary shares: GB00B63PS212

b)

Nature of the transaction

Grant of options

c)

Price(s) and volume(s)

 Price(s)

Volume(s)

10p

125,188

d)

Aggregated information

- Aggregated volume

- Price

N/A

e)

Date of the transactions

16 March 2023

f)

Place of the transaction

Outside a trading venue

 

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Matthew White

2

Reason for the notification

a)

Position/status

Chief Commercialisation Officer

b)

 

Initial notification /Amendment

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Frontier IP Group plc

b)

LEI

213800BRYUKQPJWKJ312

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Identification code

Options over ordinary shares of 10p each in Frontier IP Group Plc

 

Identification code (ISIN) for Frontier IP Group Plc ordinary shares: GB00B63PS212

b)

Nature of the transaction

Grant of options

c)

Price(s) and volume(s)

 Price(s)

Volume(s)

10p

125,188

d)

Aggregated information

- Aggregated volume

- Price

N/A

e)

Date of the transactions

16 March 2023

f)

Place of the transaction

Outside a trading venue

 

 

 

ENQUIRIES

 

Frontier IP Group Plc

Neil Crabb, Chief Executive

Andrew Johnson, Communications and Investor Relations

andrew.johnson@frontierip.co.uk

Company website: www.frontierip.co.uk 

 

T: 020 3968 7815 neil@frontierip.co.uk

M: 07464 546 025

Allenby Capital Limited (Nominated Adviser)

Nick Athanas / George Payne

 

T: 0203 328 5656

Singer Capital Markets (Broker)

Sandy Fraser / Harry Gooden / George Tzimas

T: 0207 496 3000

 

 

ABOUT FRONTIER IP

Frontier IP unites science and commerce by identifying strong intellectual property and accelerating its development through a range of commercialisation services. A critical part of the Group's work is involving relevant industry partners at an early stage of development to ensure technology meets real world demands and needs.

The Group looks to build and grow a portfolio of equity stakes and licence income by taking an active involvement in spin-out companies, including support for fund raising and collaboration with relevant industry partners at an early stage of development.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHSFSFLWEDSELD
Date   Source Headline
17th Apr 20241:59 pmRNSHolding(s) in Company
12th Apr 20247:00 amRNSAppointment of Chief Financial Officer
2nd Apr 202412:44 pmRNSHolding(s) in Company
14th Mar 20247:00 amRNSUnaudited Half Year Results
4th Mar 20241:40 pmRNSHolding(s) in Company
29th Feb 20243:12 pmRNSSale of shares in Exscientia
30th Jan 202411:45 amRNSHolding(s) in Company
22nd Jan 20247:00 amRNSOctopus invest in Alusid as part of equity funding
29th Dec 202312:00 pmRNSTotal Voting Rights
19th Dec 20234:46 pmRNSHolding(s) in Company
15th Dec 20236:12 pmRNSReplacement - Result of AGM and Directorate Change
15th Dec 20232:07 pmRNSResult of AGM and Directorate Change
13th Dec 20237:00 amRNSPortfolio news - The Vaccine Group
11th Dec 20237:00 amRNSHolding(s) in Company
30th Nov 20235:00 pmRNSTotal Voting Rights
30th Nov 20237:00 amRNSExercise of Options & Director/PDMR Shareholdings
28th Nov 20237:00 amRNSBoard Change
21st Nov 20237:00 amRNSPosting of Annual Report and Notice of AGM
9th Nov 20235:27 pmRNSHolding(s) in Company
3rd Nov 20237:05 amRNSGrant of options
1st Nov 20235:48 pmRNSExercise of Options & PDMR Shareholdings & TVR
31st Oct 20237:01 amRNSBoard changes
31st Oct 20237:00 amRNSFinal results for the year ended 30 June 2023
23rd Oct 20237:00 amRNSNew portfolio company Deakin Bio-Hybrid Materials
12th Oct 20232:05 pmRNSHolding(s) in Company
21st Sep 20237:00 amRNSExscientia announces collaboration with Merck
14th Sep 20235:21 pmRNSHolding(s) in Company
14th Sep 20237:00 amRNSExercise of Options & Total Voting Rights
11th Sep 20237:00 amRNSPortfolio news – Pulsiv appoints Chairman and CPO
8th Sep 20237:00 amRNSExercise of Options & Total Voting Rights
10th Aug 20238:45 amRNSPortfolio news – Fieldwork Robotics
24th Jul 20237:00 amRNSPortfolio news – CamGraPhIC loan facility
20th Jul 20235:18 pmRNSHolding(s) in Company
1st Jun 20237:00 amRNSSale of shares in Exscientia
26th May 20236:06 pmRNSHolding(s) in Company
9th May 20237:00 amRNSTopps Tiles launches first Alusid made tile range
21st Apr 20234:00 pmRNSDirectorate Change
20th Apr 20235:26 pmRNSHolding(s) in Company
27th Mar 20235:17 pmRNSHolding(s) in Company
17th Mar 20232:46 pmRNSGrant of options
15th Mar 20237:00 amRNSBoard changes
15th Mar 20237:00 amRNSUnaudited Half Year Results
30th Jan 20237:00 amRNSAlusid in collaboration with Imerys
9th Jan 20237:00 amRNSCelerum appoints David Gladding as CEO
9th Dec 20224:08 pmRNSResult of AGM
7th Dec 20221:25 pmEQSThe Vaccine Group completes two deadly disease vaccination projects
6th Dec 20227:00 amRNSFrontier IP to host Portfolio Demo Day
5th Dec 20227:00 amRNSThe Vaccine Group completes Lassa fever project
2nd Dec 20227:00 amRNSThe Vaccine Group completes vaccine project
30th Nov 20225:00 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.